Armand Butera

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

Dr. Karan Lal offers insights into diagnosing various forms of rosacea as well as common treatment methods.

Dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.

This is the first topical treatment approved by the FDA for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years and older.

Previous research suggested that inpatient dermatology services not only improved diagnostic accuracy but reduced readmissions.

No specific inflammatory pathway was considered causative to long-term mortality in kidney transplant recipients.

When combined with corticosteroids, the oral therapy appeared to be as effective as IVCY with a more favorable safety profile.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

Previously, few rapid diagnostic tests have been studied in home environments, and there are currently no tests approved for at-home influenza detection by the Food and Drug Administration (FDA)

The VALIANT study featured a cross-sectional online survey that was used to recruit adult patients 18 years and older who were professionally diagnosed with vitiligo.

Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.

Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.

The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.

The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.

New phase 2 data from the KARE study presented at AAD found that the therapy improved itch severity and sleep in patients with atopic dermatitis and pruritis.

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.

Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.

New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

Dupilumab is the first biologic to show positive phase 3 results in patients with prurigo nodularis.

New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

Dr. Elena B. Hawryluk details her pre-AAD session, the variety of conversations being held at the meeting, and how these conversations can inform dermatological research outside of the pediatric field.

Dr. Rees spoke of how addressing issues of representation could improve upon disparities in health care not only in the pediatric space but across all fields.

IL-17 inhibitors were also associated with higher persistence than IL-12 and IL-23 inhibitors for psoriatic arthritis, though no difference was observed for psoriasis.

Investigators found that a starch- and sucrose-reduced diet (SSRD) increased the intake of several micronutrients which correlated weakly with symptom improvement.